glofitamab glofitamab glofitamab, sold under the brand name columvi is a bispecific monoclonal antibody used for the treatment of diffuse large b-cell lymphoma. glofitamabmonoclonal antibodytypewhole antibodysourcehumanizedtargetcd20 and cd3clinical datatrade namescolumviother namesro7082859routes ofadministrationintravenousdrug classantineoplasticatc codenonelegal statuslegal status ca: ℞-only / schedule d identifierscas number2229047-91-8drugbankdb16371unii06p3klk2j8keggd11833chemical and physical dataformulac8632h13326n2296o2701s58molar mass194344.41 g·mol−1 it was approved for medical use in canada in march 2023. society and culture legal status on 26 april 2023, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product columvi, intended for the treatment of diffuse large b‑cell lymphoma (dlbcl). the applicant for this medicinal product is roche registration gmbh. names glofitamab is the international nonproprietary name.